Natera, Inc. (NASDAQ:NTRA) CFO Sells $88,785.50 in Stock

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CFO Michael Burkes Brophy sold 610 shares of the firm's stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $145.55, for a total transaction of $88,785.50. Following the transaction, the chief financial officer now directly owns 76,468 shares of the company's stock, valued at approximately $11,129,917.40. This trade represents a 0.79 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Michael Burkes Brophy also recently made the following trade(s):

• On Wednesday, April 23rd, Michael Burkes Brophy sold 495 shares of Natera stock. The shares were sold at an average price of $150.74, for a total transaction of $74,616.30.
• On Monday, March 31st, Michael Burkes Brophy sold 2,562 shares of Natera stock. The stock was sold at an average price of $138.41, for a total transaction of $354,606.42.
• On Monday, March 17th, Michael Burkes Brophy sold 792 shares of Natera stock. The shares were sold at an average price of $146.04, for a total transaction of $115,663.68.
• On Monday, February 3rd, Michael Burkes Brophy sold 43,502 shares of Natera stock. The stock was sold at an average price of $176.88, for a total transaction of $7,694,633.76.
• On Wednesday, January 29th, Michael Burkes Brophy sold 4,335 shares of Natera stock. The stock was sold at an average price of $165.87, for a total value of $719,046.45.
• On Friday, January 31st, Michael Burkes Brophy sold 1,886 shares of Natera stock. The shares were sold at an average price of $176.60, for a total value of $333,067.60.
• On Monday, January 27th, Michael Burkes Brophy sold 1,442 shares of Natera stock. The shares were sold at an average price of $161.87, for a total value of $233,416.54.
• On Friday, January 24th, Michael Burkes Brophy sold 946 shares of Natera stock. The stock was sold at an average price of $171.98, for a total transaction of $162,693.08.

Natera Stock Down 1.7 %

NASDAQ:NTRA traded down $2.69 on Monday, reaching $151.11. The stock had a trading volume of 361,939 shares, compared to its average volume of 1,379,527. Natera, Inc. has a 12-month low of $90.88 and a 12-month high of $183.00. The stock has a market cap of $20.43 billion, a P/E ratio of -85.61 and a beta of 1.80. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The company has a 50-day moving average of $147.95 and a 200 day moving average of $153.71.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, beating analysts' consensus estimates of ($0.42) by $0.01. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm had revenue of $476.10 million during the quarter, compared to analyst estimates of $447.91 million. On average, research analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.

Analyst Ratings Changes

NTRA has been the subject of several research analyst reports. Canaccord Genuity Group reaffirmed a "buy" rating and set a $180.00 price target on shares of Natera in a research report on Wednesday, February 26th. Sanford C. Bernstein upped their price target on Natera from $160.00 to $200.00 and gave the stock an "outperform" rating in a research note on Friday, January 10th. BTIG Research reaffirmed a "buy" rating on shares of Natera in a research note on Friday, February 28th. The Goldman Sachs Group increased their target price on shares of Natera from $160.00 to $190.00 and gave the stock a "buy" rating in a research report on Tuesday, January 28th. Finally, Barclays reduced their price target on shares of Natera from $200.00 to $160.00 and set an "overweight" rating on the stock in a research report on Thursday, April 10th. One analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $175.76.

Institutional Trading of Natera

Institutional investors have recently added to or reduced their stakes in the stock. Wilmington Savings Fund Society FSB bought a new stake in shares of Natera in the 3rd quarter worth about $385,000. Everence Capital Management Inc. acquired a new position in Natera in the fourth quarter worth about $573,000. Smartleaf Asset Management LLC increased its holdings in Natera by 50.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 657 shares of the medical research company's stock valued at $104,000 after buying an additional 220 shares during the last quarter. SeaBridge Investment Advisors LLC acquired a new stake in Natera during the fourth quarter valued at approximately $2,894,000. Finally, SYM FINANCIAL Corp bought a new position in Natera during the 4th quarter worth approximately $256,000. 99.90% of the stock is owned by institutional investors and hedge funds.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.